Recent investigations have focused on the overlap of GLP|GIP|glucagon receptor activator therapies and dopamine signaling. While GLP agonists are widely employed for managing type 2 diabetes, their potential consequences on reinforcement circuits, specifically governed by DA networks, are receiving significant attention. This article provides a con